IGC Pharma
26 hedge funds and large institutions have $1M invested in IGC Pharma in 2019 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 5 increasing their positions, 5 reducing their positions, and 3 closing their positions.
153% more capital inflows, than outflows
Capital inflows: $167K | Capital outflows: $65.9K
33% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 3
0.21% more ownership
Funds ownership: 3.82% → 4.03% (+0.21%)
0% more funds holding
Funds holding: 26 → 26 (0)
0% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 5
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $3K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Virtu Financial
New York
|
+$80.2K |
| 2 |
Truist Financial
Charlotte,
North Carolina
|
+$30K |
| 3 |
BlackRock
New York
|
+$21.9K |
| 4 |
Creative Planning
Overland Park,
Kansas
|
+$20.5K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$8.11K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$38.1K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$22.5K |
| 3 |
Cambridge Investment Research Advisors
Fairfield,
Iowa
|
-$5.23K |
| 4 |
Morgan Stanley
New York
|
-$62 |
| 5 |
Goldman Sachs
New York
|
-$1 |
IGC Hedge Fund Activity: Q4 2019 in Review
26 of the 5,094 institutional investors tracked by Wall St. Rank reported a position in IGC Pharma (IGC) for Q4 2019, worth a combined $1M — down 32% from $1.46M a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new IGC positions and 3 closed out — a net gain of 1 holder — while 5 added to existing stakes and 5 trimmed.
The largest buyer was Virtu Financial, opening a new position worth an estimated $80.2K. The largest seller was Susquehanna International Group, cutting an estimated $38.1K.
- 26 institutional investors held IGC Pharma (IGC) as of Q4 2019, unchanged from Q3 2019.
- Funds reported $1M of IGC Pharma stock for Q4 2019, down 32% quarter-over-quarter.
- 4 funds opened new IGC Pharma positions in Q4 2019 and 3 closed out, a net change of +1 holder.
- The largest IGC Pharma buyer in Q4 2019 was Virtu Financial, an estimated $80.2K added.
- The largest IGC Pharma seller in Q4 2019 was Susquehanna International Group, an estimated $38.1K sold.
Based on aggregated 13F filings for Q4 2019.